Table 3.
Characteristics of Patients With Cerebrospinal Fluid Pathogen(s)
| Pathogens | Individual CSF Prevalence | 1 Pathogen | No. of Cases | 2 Pathogens | No. of Cases | 3 Pathogens | No. of Cases | 4 Pathogens | No. of Cases |
|---|---|---|---|---|---|---|---|---|---|
| EBV | 91/331 (27.5%) | EBV | 41 | EBV/Crypto | 19 | EBV/TB/CMV | 4 | EBV/Crypto/TB/VZV | 1 |
| Cryptoa | 64/331 (19.3%) | Crypto | 35 | EBV/TB | 11 | EBV/TB/JCV | 1 | Crypto/TB/VZV/CMV | 1 |
| TB | 48/331 (14.5%) | TB | 20 | EBV/VZV | 3 | EBV/TB/Meningo | 1 | ||
| JCV | 20/331 (6.0%) | JCV | 9 | EBV/JCV | 2 | EBV/TB/Crypto | 1 | ||
| CMV | 20/331 (6.0%) | CMV | 6 | EBV/Pneumo | 2 | EBV/Crypto/JCV | 1 | ||
| VZV | 13/331 (3.9%) | VZV | 4 | EBV/CMV | 1 | EBV/JCV/CMV | 1 | ||
| Pneumo | 8/331 (2.4%) | HSV-1 | 2 | EBV/HSV-1 | 1 | EBV/JCV/VZV | 1 | ||
| HSV-1 | 5/331 (1.5%) | HSV-2 | 0 | Crypto/CMV | 2 | ||||
| Meningo | 2/331 (0.6%) | Toxo | 0 | Crypto/VZV | 2 | ||||
| HSV-2 | 0/331 (0%) | Pneumo | 4 | Crypto/TB | 1 | ||||
| Toxo | 0/331 (0%) | Crypto/HSV-1 | 1 | ||||||
| TB/CMV | 4 | ||||||||
| TB/JCV | 2 | ||||||||
| TB/VZV | 1 | ||||||||
| JCV/Pneumo | 2 | ||||||||
| JCV/HSV-1 | 1 | ||||||||
| CMV/Meningo | 1 | ||||||||
| Totals | 271 pathogens | 121/331 (36.6%) | 56/331 (16.9%) | 10/331 (3%) | 2/331 (0.6%) |
Abbreviations: CMV, cytomegalovirus; Crypto, Cryptococcus neoformans; CSF, cerebrospinal fluid; EBV, Epstein-Barr virus; HSV, herpes simplex virus; JCV, JC virus; Meningo, meningococcus; Pneumo, pneumococcus; TB, Mycobacterium tuberculosis; Toxo, Toxoplasma gondii; VZV, varicella zoster virus.
a One hundred eighty-four of 331 (55.6%) patients had sufficient testing.